Global Acromegaly and Gigantism Drugs Market 2018-2022
About Acromegaly and Gigantism Drugs
The acromegaly and gigantism are GH-related diseases. Acromegaly disease occurs in adults while gigantism occurs in children.
Technavio’s analysts forecast the global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global acromegaly and gigantism drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of acromegaly and gigantism drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Acromegaly and Gigantism Drugs Market 2018-2022
Technavio recognizes the following companies as the key players in the global acromegaly and gigantism drugs market: Ipsen, Novartis, and Pfizer
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is growing popularity of drugs over surgeries. Although pharmacological therapies for acromegaly treatment have been there for more than a decade, the demand from individuals for these non-surgical options is increasing on a regular basis. The prime reason for the shift in choice can be attributed to low success rates of acromegaly surgeries. For instance, as per the NIH, in a study involving total 62 subjects, 31 subjects were treated by transsphenoidal surgery, and four subjects were cured. Out of these 31 subjects treated with transsphenoidal surgery, post-operative anterior pituitary hormone deficiency was seen in 10 subjects, and diabetes insipidus got developed in one subject.”
According to the report, one of the major drivers for this market is Strong pipeline. The presence of a large number of molecules in pipeline represents significant opportunities for market growth. Around 42.86% of the total pipeline molecules for acromegaly and gigantism are in Phase III stage of development and are expected to be launched during the forecast period. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition. For instance, octreotide capsules by Chiasma and Pasireotide long-acting release (LAR) by Novartis for individuals with acromegaly who are inadequately treated with somatostatin analogs, and combination therapy of lanreotide autogel and pegvisomant by Ipsen are in Phase III stage of development for the treatment of acromegaly.
Further, the report states that one of the major factors hindering the growth of this market is Difficulty in diagnosis. In the last two decades, numerous important advancements took place in the domain such as the emergence of assays with improved sensitivity for IGF-1 and GH, development of automated software for evaluating physical changes associated with the disease, and widespread pituitary examination using magnetic resonance imaging (MRI). Despite all these advancements, acromegaly remains clinically under-diagnosed.
Ipsen, Novartis, and Pfizer